Travere Therapeutics

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Data from the four patients treated with the highest dose of pegtibatinase showed a clinically meaningful 67.1% mean relative reduction in total homocysteine from baseline

Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria

FILSPARI's inability to significantly change FSGS disease trajectory (eGFR) in the Phase 3 DUPLEX study raises doubts about its IgAN trial and eventual approvability in FSGS. FILSPARI's sales, largely inventory-driven, may not predict actual market potential. We downgrade to sell rating as we are bearish on the PROTECT readout and also believe the upcoming sales data won't be a meaningful enough catalyst to change the trajectory.

Travere: Turbulent Journey With FILSPARI, Downgrading To Sell

LOS ANGELES, CA / ACCESSWIRE / May 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

BioMarin Pharmaceutical

Novo Nordisk

When it comes to possibilities of outsized rewards, few sectors can beat out biotech stocks with blockbuster potential. Fundamentally, the underlying sector enjoys a massive footprint.

3 Biotech Stocks With Blockbuster Potential

LOS ANGELES, CA / ACCESSWIRE / May 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 46,000 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES, CA / ACCESSWIRE / May 10, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Naomi Eichenbaum - VP, IR Eric Dube - President, CEO and Director Jula Inrig - Chief Medical Officer Christopher Cline - CFO Peter Heerma - Chief Commercial Officer William Rote - SVP, Research and Development Conference Call Participants Maury Raycroft - Jefferies Greg Harrison - Bank of America Joseph Schwartz - SVB Securities Leon Wang - Barclays Liisa Bayko - Evercore ISI Laura Chico - Wedbush Securities Vamil Divan - Guggenheim Securities Alex Thompson - Stifel Ed Arce - HC Wainwright Operator Good day, and welcome to the Travere Therapeutics First Quarter 2023 Financial Results and Corporate Update Conference Call. Today's conference is being recorded.

Travere Therapeutics, Inc. (TVTX) Q1 2023 Earnings Call Transcript

Travere Therapeutics (TVTX) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to loss of $1.20 per share a year ago.

Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates

FILSPARI™(sparsentan) granted accelerated approval by FDA for the reduction of proteinuria in IgA nephropathy (IgAN) on February 17 th , 2023; commercial launch underway

Travere Therapeutics Reports First Quarter 2023 Financial Results

Travere Therapeutics Inc.'s stock TVTX tumbled 35% Tuesday, after the company said data from a two-year study of a kidney drug failed to show a statistically significant improvement. The company said the Phase 3 trial of Sparsentan as a treatment for focal segmental glomerulosclerosis, or FSGS, did not meet the primary efficacy eGFR slope endpoint over 108 weeks of treatment.

Travere Therapeutics stock slides 35% after announcing disappointing results from 2-year trial of kidney drug

LOS ANGELES--(BUSINESS WIRE)---- $TVTX #TVTX--The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Travere Therapeutics offered a disappointing update from a two-year study in kidney disease, and TVTX stock crashed Tuesday. The post Travere Crashes 29% On A Disappointing Update From A Two-Year Kidney Disease Test appeared first on Investor's Business Daily.

Travere Crashes 29% On A Disappointing Update From A Two-Year Kidney Disease Test

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with sparsentan resulted in a reduction of proteinuria that was sustained through 108 weeks of treatment Sparsentan was well-tolerated with a consistent safety profile across all clinical trials conducted to date and comparable to irbesartan Company to host conference call and webcast today at 4:30pm ET SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) --  Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), in focal segmental glomerulosclerosis (FSGS). At the end of the 108-week double-blind period, sparsentan was observed to have a 0.3 mL/min/1.73m2 per year (95% CI: -1.74, 2.41) favorable difference on eGFR total slope and a 0.9 mL/min/1.73m2 per year (95% CI: -1.27, 3.04) favorable difference on eGFR chronic slope compared to the active control irbesartan, which was not statistically significant.

Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

SAN DIEGO, April 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2023 financial results on Thursday, May 4, 2023, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

Travere Therapeutics to Report First Quarter 2023 Financial Results

Travere: Pegtibatinase Takes The Lead In The HCU Treatment Race.

Travere: Pegtibatinase Takes The Lead In The HCU Treatment Race

The Filspari Paradox: Travere's Promising Drug Faces Early-Stage Challenges.

The Filspari Paradox: Travere's Promising Drug Faces Early-Stage Challenges

FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control

Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023

SAN DIEGO, March 28, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences:

Travere Therapeutics to Present at Upcoming Investor Conferences

Axsome Therapeutics

Sarepta Therapeutics

Axsome already has two approved drugs and could add two more in the near future. Sarepta has significant growth opportunities with its rare-disease drugs.

3 Up-and-Coming Growth Stocks to Buy Right Now

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the interim analysis of efficacy and safety data from the ongoing Phase 3 PROTECT Study evaluating FILSPARI™ (sparsentan) in IgA nephropathy (IgAN) will be presented in late-breaking trial sessions at both the ISN World Congress of Nephrology in Bangkok, Thailand, March 30-April 2 (ISN-WCN), and NKF Spring Clinical Meetings in Austin, TX, April 11-15, 2023 (NKF).

Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023

News for Travere Therapeutics Stock (TVTX)